Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.27)
# 4,333
Out of 5,058 analysts
16
Total ratings
23.08%
Success rate
-25.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.38 | +689.47% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $2.34 | +583.76% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $2.04 | +341.18% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.80 | +110.53% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $20.46 | +388.76% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.88 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.30 | +50,134.43% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $1.74 | +762.07% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $4.51 | +365.63% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $83.00 | +8.43% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.23 | +13,801.35% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $2.50 | +1,343,900.00% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.38
Upside: +689.47%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $2.34
Upside: +583.76%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $2.04
Upside: +341.18%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.80
Upside: +110.53%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $20.46
Upside: +388.76%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.88
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.30
Upside: +50,134.43%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $1.74
Upside: +762.07%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $4.51
Upside: +365.63%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $83.00
Upside: +8.43%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.23
Upside: +13,801.35%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $2.50
Upside: +1,343,900.00%